Drugs for diabetes: Part 3 thiazolidinediones

British Journal of Cardiology

Volumn 18, Issue 1, 2011, Pages 24-27

  McGrane, David ^a   Fisher, Miles ^a   McKay, Gerard A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; METFORMIN; PIOGLITAZONE; RECEPTOR BLOCKING AGENT; ROSIGLITAZONE; SULFONYLUREA;

ARTICLE; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; EDEMA; EUROPE; FLUID RETENTION; FOOT EDEMA; GASTROINTESTINAL TOXICITY; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SELECTION; SIDE EFFECT; STROKE; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 79959819368     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Gonzalea MA, Selwyn AP. Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med 2003;115:99-106. (Pubitemid 37532900)
2. Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki MA, Cowan J. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. Health Technology Assess 2004;8(13). Available from: url:http://www.hta.ac.uk/execsumm/summ813.shtml
3. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;(3):CD006063.
4. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;(4):CD006060.
5. Kahn SE, Haffner SM, Heise MA et al. Glycaemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43. (Pubitemid 44903747)
6. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005;366:1279-89. (Pubitemid 41416583)
7. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study. J Am Coll Cardiol 2007;49:1772-80. (Pubitemid 46629127)
8. Wilcox R, Bousser MG, Betteridge DJ et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007;38:865-73. (Pubitemid 46568445)
9. Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab 2008;10:1221-38.
10. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8. (Pubitemid 47403104)
11. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71. (Pubitemid 46919772)
12. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007;1479:578-81. (Pubitemid 351664507)
13. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95. (Pubitemid 47403105)
14. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomized, open-label trial. Lancet 2009;373:2125-35.
15. Medicines and Healthcare products Regulatory Agency. Rosiglitazone: current advice on cardiovascular risk. Drug Safety Update 2010;4(1):S2.
16. Nissen SE, Wolski K. Rosiglitazone revisited. An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170:1191-201.
17. Graham DJ, Ouellet-Hellstrom R, MaCurday TE et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304:411-18.
18. Goldberg RB, Kendall DM, Deeg MA et al.; GLAI Study Investigators. A comparison of lipid and glycaemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidaemia. Diabetes Care 2005;28:1547-54. (Pubitemid 40923063)
19. Niemeyer NV, Janney LM. Thiazolidinedione-induced edema. Pharmacotherapy 2002;22:924-9. (Pubitemid 34743442)
20. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trials. Lancet 2007;370:1129-36. (Pubitemid 47464583)
21. Bolen S, Feldman L, Vassy J et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386-99. (Pubitemid 351664540)
22. Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure: AHA/ADA consensus statement. Circulation 2003;108:2941-8.